HIV and AIDS: Treatments and Medications (cont.)
In this Article
- Entry Inhibitors (including Fusion Inhibitors) and CCR5 Co-receptor Antagonist
- HIV Integrase Strand Transfer Inhibitors
- Multi-Class Combination Drugs
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- Protease Inhibitors (PIs)
HIV Integrase Strand Transfer Inhibitors
The first available drug in this class is RAL and represents a new drug in a new class that appears to be very potent at suppressing HIV in all patients who have never been on this drug or other integrase inhibitors in development. It was initially approved for treatment-experienced patients with drug-resistant virus. It is also now approved for those starting therapy for the first time. The approved dose of RAL is 400 mg twice daily.
|Brand Name||Generic Name||Manufacturer|
|Isentress||raltegravir||Merck & Co., Inc.|
Multi-Class Combination Drugs
Multi-class combination drugs are comprised of components of other antiretroviral drugs into a single pill.
|Brand Name||Generic Names||Manufacturer|
|Atripla||efavirenz, emtricitabine and tenofovir disoproxil fumarate||Bristol-Myers Squibb and Gilead Sciences|
The U.S. Food and Drug Administration
Get breaking medical news.